Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec)

Martyna Mieszczak; Marika Pitnoczko; Kinga Obst; Zuzanna Niedziela-Schwartz; Piotr Rakowicz; Maciej Krawczyński; Marcin Stopa

doi:10.5114/ko.2025.152090

POLSKI

eISSN: 2719-3209
ISSN: 0023-2157

Klinika Oczna / Acta Ophthalmologica Polonica

Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

2/2025
vol. 127

Send email

Copy url:

abstract:

Original article

Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec)

Martyna Mieszczak

¹

,

Marika Pitnoczko

¹

,

Kinga Obst

¹

,

Zuzanna Niedziela-Schwartz

¹

,

Piotr Rakowicz

¹

,

Maciej Krawczyński

^{2, 3}

,

Marcin Stopa

¹

Department of Ophthalmology, Chair of Ophthalmology and Optometry, Poznan University of Medical Sciences, Poland; University Clinical Hospital in Poznan, Poland
Department of Medical Genetics, Poznan University of Medical Sciences, Poland
Genesis Medical Genetics Center in Poznan, Poland

KLINIKA OCZNA 2025, 127, 2: 80-86

DOI: https://doi.org/10.5114/ko.2025.152090

Online publish date: 2025/06/23

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Mieszczak M, Pitnoczko M, Obst K, et al. Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec). Klinika Oczna / Acta Ophthalmologica Polonica. 2025;127(2):80-86. doi:10.5114/ko.2025.152090.

APA

Mieszczak, M., Pitnoczko, M., Obst, K., Niedziela-Schwartz, Z., Rakowicz, P.,  & Krawczyński, M. et al. (2025). Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec). Klinika Oczna / Acta Ophthalmologica Polonica, 127(2), 80-86. https://doi.org/10.5114/ko.2025.152090

Chicago

Mieszczak, Martyna, Marika Pitnoczko, Kinga Obst, Zuzanna Niedziela-Schwartz, Piotr Rakowicz, Maciej Krawczyński,  and Marcin Stopa. 2025. "Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec)". Klinika Oczna / Acta Ophthalmologica Polonica 127 (2): 80-86. doi:10.5114/ko.2025.152090.

Harvard

Mieszczak, M., Pitnoczko, M., Obst, K., Niedziela-Schwartz, Z., Rakowicz, P., Krawczyński, M.,  and Stopa, M. (2025). Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec). Klinika Oczna / Acta Ophthalmologica Polonica, 127(2), pp.80-86. https://doi.org/10.5114/ko.2025.152090

MLA

Mieszczak, Martyna et al. "Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec)." Klinika Oczna / Acta Ophthalmologica Polonica, vol. 127, no. 2, 2025, pp. 80-86. doi:10.5114/ko.2025.152090.

Vancouver

Mieszczak M, Pitnoczko M, Obst K, Niedziela-Schwartz Z, Rakowicz P, Krawczyński M et al. Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec). Klinika Oczna / Acta Ophthalmologica Polonica. 2025;127(2):80-86. doi:10.5114/ko.2025.152090.

PlumX metrics:

Introduction
Assessment of functional vision, that is, the ability to move independently and perform daily activities, is crucial in patients with inherited retinal dystrophies, such as those associated with RPE65 gene mutations. The MLMT (Multi-Luminance Mobility Test) is a standardized method for evaluating functional vision under controlled lighting conditions.

Aim of study
Assessment of MLMT results in four patients with biallelic RPE65 mutations before and after gene therapy with voretigene neparvovec (Luxturna).

Material and methods
Four patients (two with Leber congenital amaurosis and two with retinitis pigmentosa) with confirmed biallelic RPE65 gene mutations were evaluated using the MLMT before, and at 30 and 90 days after subretinal gene therapy. The MLMT was conducted at various illumination levels (1-400 lux). Scoring took into account the time to complete the course and the number of errors. The criterion for passing the test was completing the course in ≤180 seconds with ≤ 3 errors.

Results
Before therapy, patients exhibited marked difficulties in completing the test, particularly under low light intensity conditions. Following therapy, all patients demonstrated either improvement or stabilization, evidenced by reduced completion times, fewer errors, and greater accuracy.

Conclusions
The MLMT is a valuable tool for assessing functional vision in patients with RPE65 gene mutations and for monitoring the effects of gene therapy, providing objective data on functional vision under conditions that closely resemble everyday life.

keywords:

Multi-Luminance Mobility Test (MLMT) as a tool for assessing functional vision in patients with RPE65 gene mutations following gene therapy (voretigene neparvovec)

Martyna Mieszczak 1 , Marika Pitnoczko 1 , Kinga Obst 1 , Zuzanna Niedziela-Schwartz 1 , Piotr Rakowicz 1 , Maciej Krawczyński 2, 3 , Marcin Stopa 1

RPE65, MLMT, voretigene neparvovec, Luxturna

Martyna Mieszczak

¹

,

Marika Pitnoczko

¹

,

Kinga Obst

¹

,

Zuzanna Niedziela-Schwartz

¹

,

Piotr Rakowicz

¹

,

Maciej Krawczyński

^{2, 3}

,

Marcin Stopa

¹